JP2024503784A5 - - Google Patents
Info
- Publication number
- JP2024503784A5 JP2024503784A5 JP2023536859A JP2023536859A JP2024503784A5 JP 2024503784 A5 JP2024503784 A5 JP 2024503784A5 JP 2023536859 A JP2023536859 A JP 2023536859A JP 2023536859 A JP2023536859 A JP 2023536859A JP 2024503784 A5 JP2024503784 A5 JP 2024503784A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- fragment
- immunoglobulin protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063127959P | 2020-12-18 | 2020-12-18 | |
| US63/127,959 | 2020-12-18 | ||
| PCT/US2021/064073 WO2022133239A1 (en) | 2020-12-18 | 2021-12-17 | Immunoglobulin proteins that bind to npr1 agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024503784A JP2024503784A (ja) | 2024-01-29 |
| JP2024503784A5 true JP2024503784A5 (enExample) | 2024-12-24 |
Family
ID=79687048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023536859A Pending JP2024503784A (ja) | 2020-12-18 | 2021-12-17 | Ｎｐｒ１アゴニストに結合する免疫グロブリンタンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12325752B2 (enExample) |
| EP (1) | EP4263616A1 (enExample) |
| JP (1) | JP2024503784A (enExample) |
| KR (1) | KR20230132468A (enExample) |
| CN (1) | CN116964101A (enExample) |
| AU (1) | AU2021401415A1 (enExample) |
| CA (1) | CA3202629A1 (enExample) |
| CL (1) | CL2023001680A1 (enExample) |
| CO (1) | CO2023009498A2 (enExample) |
| IL (1) | IL303542A (enExample) |
| MX (1) | MX2023007023A (enExample) |
| WO (1) | WO2022133239A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7439076B2 (ja) | 2018-10-23 | 2024-02-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｎｐｒ１抗体およびその使用 |
| JP2024503784A (ja) | 2020-12-18 | 2024-01-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｎｐｒ１アゴニストに結合する免疫グロブリンタンパク質 |
| EP4415820A1 (en) * | 2021-10-11 | 2024-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of effecting a hemodynamic change by administering an anti-npr1 antibody |
| IL313265A (en) | 2021-12-06 | 2024-08-01 | Regeneron Pharma | Antagonistic antibodies against NPR1 and methods of using them |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU2003259285A1 (en) | 2002-07-29 | 2004-02-16 | Hmgene, Inc. | Methods of identifying adipocyte specific genes, the genes identified, and their uses |
| US20080214437A1 (en) | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| NZ587107A (en) | 2006-06-02 | 2012-05-25 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| US20100310561A1 (en) | 2007-06-06 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Natriuretic fusion proteins |
| WO2010065293A1 (en) | 2008-12-03 | 2010-06-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Antibodies for guanylyl cyclase receptors |
| LT2975051T (lt) | 2009-06-26 | 2021-07-12 | Regeneron Pharmaceuticals, Inc. | Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu |
| HRP20151188T4 (hr) | 2010-02-08 | 2021-10-01 | Regeneron Pharmaceuticals, Inc. | Miš sa zajedničkim lakim lancem |
| US10184942B2 (en) | 2011-03-17 | 2019-01-22 | University Of South Florida | Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer |
| CA2818287C (en) | 2012-06-08 | 2021-11-02 | Brock University | A method of activating immune response in plants |
| LT3495387T (lt) * | 2012-07-13 | 2021-11-25 | Roche Glycart Ag | Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| RU2646098C2 (ru) * | 2013-04-30 | 2018-03-01 | Интас Фармасьютикалс Лтд | Новый способ клонирования, экспрессии и очистки для получения ранибизумаба |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| WO2016131943A1 (en) | 2015-02-20 | 2016-08-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes |
| WO2017209553A2 (ko) | 2016-06-03 | 2017-12-07 | 사회복지법인 삼성생명공익재단 | 환자 유래 세포를 이용한 항체 스크리닝 방법 |
| US20190248888A1 (en) | 2016-10-20 | 2019-08-15 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| JP2020522498A (ja) * | 2017-06-01 | 2020-07-30 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ１２３ ｃｄ３に結合する二重特異性抗体 |
| US20190135804A1 (en) | 2017-11-03 | 2019-05-09 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Compositions and methods for the inhibition of pruritus |
| JP7439076B2 (ja) | 2018-10-23 | 2024-02-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｎｐｒ１抗体およびその使用 |
| EP3898700A1 (en) * | 2018-12-18 | 2021-10-27 | Novartis AG | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
| CN113966345B (zh) * | 2019-06-12 | 2024-12-13 | 诺华股份有限公司 | 利钠肽受体1抗体及使用方法 |
| US20240052042A1 (en) | 2020-12-14 | 2024-02-15 | Novartis Ag | Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof |
| JP2024503784A (ja) | 2020-12-18 | 2024-01-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｎｐｒ１アゴニストに結合する免疫グロブリンタンパク質 |
| IL313265A (en) | 2021-12-06 | 2024-08-01 | Regeneron Pharma | Antagonistic antibodies against NPR1 and methods of using them |
-
2021
- 2021-12-17 JP JP2023536859A patent/JP2024503784A/ja active Pending
- 2021-12-17 IL IL303542A patent/IL303542A/en unknown
- 2021-12-17 CN CN202180093936.1A patent/CN116964101A/zh active Pending
- 2021-12-17 US US17/554,276 patent/US12325752B2/en active Active
- 2021-12-17 AU AU2021401415A patent/AU2021401415A1/en active Pending
- 2021-12-17 CA CA3202629A patent/CA3202629A1/en active Pending
- 2021-12-17 KR KR1020237024056A patent/KR20230132468A/ko active Pending
- 2021-12-17 MX MX2023007023A patent/MX2023007023A/es unknown
- 2021-12-17 WO PCT/US2021/064073 patent/WO2022133239A1/en not_active Ceased
- 2021-12-17 EP EP21844504.7A patent/EP4263616A1/en active Pending
-
2023
- 2023-06-09 CL CL2023001680A patent/CL2023001680A1/es unknown
- 2023-07-17 CO CONC2023/0009498A patent/CO2023009498A2/es unknown
-
2025
- 2025-05-13 US US19/206,976 patent/US20250333524A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7375122B2 (ja) | ヒト化、マウスまたはキメラ抗ｃｄ４７モノクローナル抗体 | |
| JP7143452B2 (ja) | ＣＤ４７とＳＩＲＰａの相互作用を遮断できる抗体及びその応用 | |
| JP2023123726A5 (enExample) | ||
| US12624094B2 (en) | Factor H potentiating antibodies and uses thereof | |
| JP2017514461A5 (enExample) | ||
| JP2018535650A5 (enExample) | ||
| RU2019140602A (ru) | АНТИ-GARP-TGF-β-АНТИТЕЛА | |
| JP2010501164A5 (enExample) | ||
| JP2024541680A5 (enExample) | ||
| US20210040213A1 (en) | Immunomonotherapy for urothelial carcinoma | |
| JP2013519367A5 (enExample) | ||
| JP2022545741A5 (enExample) | ||
| WO2014065402A1 (ja) | 抗ヒトｃｄ４０モノクローナル抗体及びその利用 | |
| JP2024024114A5 (enExample) | ||
| WO2021249542A1 (en) | Antibodies binding tnfr2 and uses thereof | |
| JP2023506465A5 (enExample) | ||
| JP2021511387A5 (enExample) | ||
| WO2020169062A1 (zh) | 抗pd-l1抗体及其用途 | |
| JP2025500411A (ja) | 抗ｃｄ１９抗体療法のための治療パラダイム | |
| JP2023536631A5 (enExample) | ||
| CN120603852A (zh) | 一种fap/cd40结合分子的药物组合物及其医药用途 | |
| CN115819582A (zh) | Pvrig的抗体或其抗原结合片段及其应用 | |
| JP2024523514A5 (enExample) | ||
| JP2021521201A5 (enExample) | ||
| JP2023534779A5 (enExample) |